Compare Braze Inc (BRZE) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Cronos Group Inc — how do they compare? Braze Inc trades at $28.27 (market cap $3.24B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Braze Inc is far larger — about 2.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | CRON | |
|---|---|---|
Market Cap | $3.24B | $1.11B |
Sector | Technology | Health |
52-Week High | $36.19 | $3.27 |
52-Week Low | $15.79 | $2.30 |
Enterprise Value | $2.93B | $310.67M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $26.54, up 3.23% with bullish technical signals from moving averages. The company shows strong revenue growth trajectory from $238M in 2022 to $593M in 2025, though profitability remains elusive with a -15.51% net margin. Recent Q1 2027 earnings met expectations at $0.10 per share, while analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $34.78 consensus target representing 31% upside potential.
The investment case hinges on Braze's accelerating revenue growth and market leadership in customer engagement software, offset by persistent losses and insider selling. While technical indicators support near-term momentum, execution on profitability remains the key catalyst for sustained upside. Risks include competitive pressures and the company's ability to convert growth into sustainable earnings.
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
